Advances in therapy of multiple myeloma: Lessons from acute leukemia

Clinical Cancer Research

Volumn 3, Issue 12 II, 1997, Pages 2605-2613

  Barlogie, Bart ^a,b  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; BUSULFAN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; MELPHALAN; NITROSOUREA DERIVATIVE; VINCRISTINE;

ACUTE LEUKEMIA; ALGORITHM; ALLOTRANSPLANTATION; AUTOLOGOUS BONE MARROW TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CHROMOSOME TRANSLOCATION; CLINICAL TRIAL; CONFERENCE PAPER; HISTORY; HUMAN; MULTIPLE MYELOMA; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; PROGNOSIS; STEM CELL TRANSPLANTATION;

ACUTE DISEASE; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS; COMBINED MODALITY THERAPY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA; MULTIPLE MYELOMA; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS;

EID: 0031408766     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (81)

1. Freireich, E. J, Gehan, E. A., Sulman, D., Boggs, D. R., and Frei, E., III. The effect of chemotherapy on acute leukemia in the human. J. Chronic Dis., 14: 593-608, 1961.
2. Freireich, E. J, and Frei, E., III. Recent advances in acute leukemia. In: C. V. Moore and E. B. Brown (eds.), Progress in Hematology, pp. 189-202. New York: Grune and Stratton, 1964.
3. Whitecar, J. P., Jr., Bodey, G. P., Freireich, E. J, McCredie, K. B., and Hart, J. S. Cyclophosphamide, vincristine, 1-β-D-arabinofuranosyl-cytosine, and prednisone (COAP) combination chemotherapy for adult acute leukemia. Cancer Chemother. Rep., 56; 543-550, 1972.
4. Rodriguez, V., Hart, J. S., Freireich, E. J, Bodey, G. P., McCredie, K. B., Whitecar, J. P., and Coltman, C. A. POMP combination chemotherapy of adult acute leukemia. Cancer (Phila.), 32: 69-75, 1973.
5. Bodey, G. P., Freireich, E. J, McCredie, K. B., Rodriguez, V., Gutterman, J. U., and Burgess, M. A. Late intensification therapy for acute leukemia in remission: chemotherapy and Immunotherapy. J. A. Med. Assoc., 235: 1021-1025, 1976.
6. Bodey, G. P., Rodriguez, V., McCredie, K. B., and Freireich, E. J. Early consolidation chemotherapy for adults with acute leukemia in remission. Med. Pediatr. Oncol., 2: 299-307, 1976.
7. Gehan, E. A., and Freireich, E. J. Non-randomized controls in cancer clinical trials. N. Engl. J. Med., 290: 198-203, 1974.
8. Freireich, E. J, and Gehan, E. A. Historical controls reincarnated: an examination of techniques for clinical therapeutic research. Cancer Chemother. Rep., 58: 623-626, 1974.
9. Freireich, E. J, Gehan, E. A., Bodey, G. P., Hersh, E. M., Hart, J. S., Gutterman, J. U., and McCredie, K. B. New prognostic factors affecting response and survival in adult acute leukemia. Trans. Assoc. Am. Phys., 87: 298-305, 1974.
10. Trujillo, J. M., Cork, A., Hart, J. S., George, S. L., and Freireich, E. J. Clinical implications of aneuploid cytogenetic profiles in adult acute leukemia. Cancer (Phila.), 33: 824-834, 1974.
11. Keating, M. J., Cork, A., Broach, Y., Smith, T., Walters, R. S., McCredie, K. B., Trujillo, J., and Freireich, E. J. Toward a clinically relevant cytogenetic classification of acute myelogenous leukemia. Leukemia Res., 11: 119-133, 1987.
12. Freireich, E. J. (ed.). New Approaches to the Treatment of Leukemia, pp. 1-193. Berlin: Springer-Verlag, 1990.
13. Freireich, E. J, Schmidt, P. J., Schneiderman, M. A., and Frei, E., III. A comparative study of the effect of transfusion of fresh and preserved whole blood on bleeding in patients with acute leukemia. N. Engl. J. Med., 260: 6-11, 1959.
14. Kliman, A., Gaydos, L. A., Shroeder, L. R., and Freireich, E. J. Repeated plasmapheresis of blood donors as a source of patients. Blood, 18: 303-309, 1961.
15. Freireich, E. J, Kliman, A., Gaydos, L. A., Mantel, N., and Frei, E., III. Response to repeated platelet transfusions from the same donor. Ann. Intern. Med., 59: 277-287, 1963.
16. Freireich, E. J, Judson, G., and Levin, R. H. Separation and collection of leukocytes. Cancer Res., 25: 1516-1520, 1965.
17. Bodey, G. P., Buckley, M., Sathe, Y. S., and Freireich, E. J. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann. Intern. Med., 64: 328-340, 1966.
18. Alexanian, R., Haut, A., Khan, A., Lane, M., McKelvey, E., Migliore, P., Stuckey, W., Jr., and Wilson, H. Treatment of multiple myeloma. Combination chemotherapy with different melphalan dose regimens. J. Am. Med. Assoc., 208: 1680-1685, 1969.
19. Alexanian, R. Ten year survival in multiple myeloma. Arch. Intern. Med., 145: 2073-2074, 1985.
20. Kyle, R. A. Long-term survival in multiple myeloma. N. Engl. J. Med., 308: 314-316, 1983.
21. Barlogie, B. Plasma cell myeloma. In: E. Beutler, M. A. Lichtman, B. S. Coller, and T. J. Kipps (eds.), William's Hematology, pp. 1109-1126. New York: McGraw-Hill, 1995.
22. Bergsagel, D. E., Bailey, A. J., Langley, G. R., MacDonald, R. N., White, D. F., and Miller, A. B. The chemotherapy of plasma-cell myeloma and the incidence of acute leukemia. N. Engl. J. Med., 301: 743-748, 1979.
23. Boccadoro, M., Marmont, F., Tribalto, M., Avvisati, G., Andriani, A., Barbui, T., Cantonetti, M., Carotenuto M., Comotti, B., Dammacco, F., Freiri, R., Gallamini, A., Gallone, G., Giobangrossi, P., Grignani, F., Lauta, V., Liberati, M., Musto, P., Neretto, G., Petrucci, M., Resegotti, L., Pileri, A., and Mandelli, F. VMCP/VBAP alternating combination chemotherapy is not superior to melphalan and prednisone even in high-risk patients. J. Clin. Oncol., 9: 444-448, 1991.
24. Belch, A., Shelley, W., Bergsagel, D., Wilson, K., Klimo, P., White, D., and Willan, A. A randomized trial of maintenance versus no maintenance melphalan and prednisone in responding multiple myeloma patients. Br. J. Cancer, 57: 94, 1988.
25. Barlogie, B., Smith, L., and Alexanian, R. Effective treatment of advanced multiple myeloma refractory to alkylating agents. N. Engl. J. Med., 310: 1353-1356, 1984.
26. Alexanian, R., Barlogie, B., and Tucker, S. VAD-based regimens as primary treatment for multiple myeloma. Am. J. Hematol., 33: 86-89, 1990.
27. Sampson, D., Gaminara, E., Newland, A., Van de Pette, J., Kearney, J., McCarthy D., Joyner, M., Aston, L., Mitchell, T., and Hamom, M. Infusion of vincristine and doxorubicin with oral dexamethasone as first-line therapy for multiple myeloma. Lancet, 335: 52-53, 1990.
28. Hata, H., Xiao, H. Q., Petrucci, M. T., Woodliff, J., and Epstein, J. Interleukin-6 gene expression in multiple myeloma: a characteristic of immature tumor cells. Blood, 81: 3357-3364, 1993.
29. Barlogie, B., Epstein, J., Selvanayagam, P., and Alexanian, R. Plasma cell myeloma: new biologic insights and advances in therapy. Blood, 73: 865-879, 1989.
30. McElwain, T. J., and Powles, R. J. High-dose intravenous melphalan for plasma-cell leukemia and myeloma. Lancet, 2: 822-824, 1983.
31. Barlogie, B., Hall, R., Zander, A., Dicke, K., and Alexanian, R. High dose melphalan with autologous bone marrow transplantation for multiple myeloma. Blood, 67: 1298-1301, 1986.
32. Barlogie, B., Alexanian, R., Dicke, K., Zagars, G., Spitzer, G., Jagannath, S., and Horowitz, L. High dose chemoradiotherapy and autologous bone marrow transplantation for resistant multiple myeloma. Blood, 70: 869-872, 1987.
33. Latreille, J., Barlogie, B., Dosik, G., Johnston, D. A., Drewinko, B., and Alexanian, R. Cellular DNA content as a marker of human multiple myeloma. Blood, 55: 403-408, 1980.
34. Drewinko, B., Alexanian R., Boyer H., Barlogie, B., and Rubinow, S. I. The growth fraction of human myeloma cells. Blood, 57: 333-338, 1981.
35. Barlogie, B., Jagannath, S., Desikan, K. R., Siegel, D., Vesole, D., and Tricot, G. Autotransplants for multiple myeloma-10 years later, in press. Garden Jennings Publishers, 1997.
36. Jagannath, S., Tricot, G., Desikan, K. R., Naucke, S., Mattox, S., Dicke, K., and Barlogie, B. 20% 9 year survival after high dose therapy (HDT) ± ABMT for high risk myeloma (MM) ≤ age 50 or B2M ≤ 2.5 mg/L pre-HDT. Blood, 88: 131a, 1996.
37. Gianni, A. M., Siena, S., Bregni M., Tarella, C., Stern, A. C., Pileri, A., and Bonadonna, G. Granulocyte-macrophage colony-stimulating factor to harvest circulating hematopoietic stem cells for autotransplantation. Lancet, 2: 580-585, 1989.
38. Tricot, G., Jagannath, S., Vesole, D. H., Nelson, J., Tindle, S., Miller, L., Cheson, B., Crowley, J., and Barlogie, B. Peripheral blood stem cell transplants for multiple myeloma-identification of favorable variables for rapid engraftment in 225 patients. Blood, 85: 588-596, 1995.
39. Jagannath, S., Vesole, D. H., Glenn, L., Crowley, J., and Barlogie, B. Low risk intensive therapy for multiple myeloma with combined autologous bone marrow and blood stem cell support. Blood, 80: 1666-1972, 1992.
40. Barlogie, B., Jagannath, S., and Tricot, G. Advances in treatment of multiple myeloma. In: R. W. Schrier (ed.), Advances in Internal Medicine, in press. Chicago: Mosby-Year Book, Inc., 1997.
41. Vescio, R. A., Hong, C. H., Cao, J., Schiller, K. A., Lichtenstein, A. K., Berenson, R. J., Berenson, J. R. The hematopoietic stem cell antigen, CD34, is not expressed on the malignant cells in multiple myeloma. Blood, 84: 3283-3290, 1994.
42. - stem cells do not contain clonal myeloma cells. Blood, 86: 381-389, 1995.
43. Gazitt, Y., Tian, E., Barlogie, B., Reading, C., Vesole, D., Jagannath, S., Schnell, J., Hoffman, R., and Tricot, G. Differential mobilization of myeloma cells and normal hematopoietic stem cells in multiple myeloma following treatment with cyclophosphamide and granulocyte-macrophage colony-stimulating factor. Blood, 87: 805-811, 1995.
44. Bensinger, W., Singer, J., Appelbaum, F., Lilleby, K., Longin, K., Rowley, S., Clarke, E., Clift, R., Hansen, J., Shields, T., Storb, R., Weaver, C., Weiden, P., and Buckner, C. D. Autologous transplantation with peripheral blood mononuclear cells collected after administration of recombinant granulocyte stimulating factor. Blood, 81: 3158-3163, 1993.
45. Desikan, K. R., Jagannath, S., Siegel, D., Munshi, N., Bracy, D., Barlogie, B., and Tricot, G. Post-transplantation engraftment kinetics and toxicities in multiple myeloma (MM) patients (PTS) are comparable following mobilization of PBSC with G-CSF with our without high dose cyclophosphamide (HDCTX). Blood, 88: 679a, 1996.
46. Barlogie, B., Velasquez, W. S., Alexanian, R., and Cabanillas, F. Etoposide, dexamethasone, cytarabine, and cisplatin in vincristine, doxorubicin, and dexamethasone-refractory myeloma. J. Clin. Oncol., 7: 1514-1517, 1989.
47. Jagannath, S., Tricot, G., Vesole, D., Desikan, K. R., Munshi, N., Siegel, D., Crowley, J., Bracy, D., Mattox, S., Naucke, S., and Barlogie, B. Total therapy (TT) with tandem autotransplants (2 TX) for 231 newly diagnosed patients (PTS) with multiple myeloma (MM). Blood, 88: 685a, 1996.
48. Tricot, G., Sawyer, J., Jagannath, S., Bracy, D., Mattox, S., Vesole, D., Naucke, S., and Barlogie, B. Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities. Blood, 86: 4250-4256, 1995.
49. Vesole, D. H., Barlogie, B., Jagannath, S., Cheson, B., Tricot, G., Alexanian, R., and Crowley, J. High-dose therapy for refractory multiple myeloma: improved prognosis with better supportive care and double transplants. Blood, 84: 950-956, 1994.
50. Vesole, D. H., Tricot, G., Jagannath, S., Desikan, K. R., Bracy, D., Miller, L., Cheson, B., Crowley, J., and Barlogie, B. Autotransplants in multiple myeloma: what have we learned? Blood, 88: 838-847, 1996.
51. Tricot, G., Sawyer, J., Jagannath, S., Desikan, K. R., Siegel, D., Naucke, S., Mattox, S., Bracy, D., Munshi, N., and Barlogie, B. The unique role of cytogenetics in the prognosis of patients with multiple myeloma receiving high dose therapy and autotransplants. J. Clin. Oncol., 15: 2659-2666, 1997.
52. Attal, M., Harousseau, J. L., Stoppa, A. M., Sotto, J. J., Fuzibet, J. G., Rossi, J. F., Casassus, P., Maisonneuve, H., Facon, T., Ifrah, N., Payen, C., and Bataillie, R. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N. Engl. J. Med., 335: 91-97, 1996.
53. Fermand, J. P., Ravaud, P., Chevret, S., Divine, M., Leblond, V., Belanger, C., Dreyfus, F., Troussard, X., Brechignac, S., Mariette, X., and Brouet, J. C. High dose therapy (HDT) and autologous blood stem cell transplantation (ABSCT) versus conventional chemotherapy with HDT rescue in multiple myeloma (MM): results of a prospective randomized trial. Blood, 86: 205a, 1995.
54. Barlogie, B., Jagannath, S., Vesole, D. H., Naucke, S., Cheson, B., Mattox, S., Bracy, D., Salmon, S., Jacobson, J., Crowley, J., and Tricot, G. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood, 89: 789-793, 1997.
55. Siegel, D. S., Jagannath, S., Desikan, K. R., Tricot, G., Bracy, D., Mattox, S., Barlogie, B., and Vesole, D. H. Feasibility of high dose chemotherapy with peripheral blood stem cell support for multiple myeloma patients over the age of 70. Blood, 88: 130a, 1996.
56. Tricot, G., Alberts, D. S., Johnson, C. S., Roe, D. J., Dorr, R. T., Vesole, D. H., Jagannath, S., Meyers, R., and Barlogie, B. Safety of autotransplants with high dose melphalan in renal failure: a pharmacokinetic and toxicity study. Clin. Cancer Res., 2: 947-952, 1996.
57. Jagannath, S., Barlogie, B., Vesole, D., Bracy, D., Mattox, S., and Tricot, G. Autotransplants (AT) can be performed safely in multiple myeloma (MM) patients with renal insufficiency. Blood, 86: 205a, 1995.
58. Tricot, G., Jagannath, S., Vesole, D. H., Crowley, J., and Barlogie, B. Relapse of multiple myeloma after autologous transplantation: survival after salvage therapy. Bone Marrow Transplant., 16: 7-11, 1996.
59. Singhal, S., Tricot, G., Jagannath, S., Mehta, J., Siegel, D., Desikan, K. R., Munshi, N., Vesole, D., Bracy, D., and Barlogie, B. Outcome of relapse after transplantation in myeloma. Blood, 88: 611a, 1996.
60. Traweek, S. T., Slowak, M. L., Nademanee, A. P., Brynes, R. K., Niland, J. C., and Forman, S. J. Myelodysplasis occurring after autologous one marrow transplantation (ABMT) for Hodgkin's disease and non-Hodgkin's lymphoma. Blood, 80: 455a, 1992.
61. Stone, R. M., Neuberg, D., Soiffer, R., Takvorian, T., Whelan, M., Rabinow, S. N., Astler, J. C., Leavitt, P., Mauch, P., Freedman, A. S., and Nadler, L. M. Myelodysplastic syndrome as a late complication following autologous bone marrow transplantation for non-Hodgkin's lymphoma. J. Clin. Oncol., 12: 2535-2542, 1994.
62. Govindarajan, R., Jagannath, S., Flick, J., Vesole, D., Sawyer, J., Barlogie, B., and Tricot, G. Preceding standard therapy is the likely cause of MDS after autotransplants for multiple myeloma. Br. J. Haematol., 95: 782-786, 1996.
63. Tricot, G., Vesole, D. H., Jagannath, S., Hilton, J., Munshi, N., and Barlogie, B. Graft-versus-myeloma effect: proof of principle. Blood, 87: 1196-1198, 1996.
64. Verdonck, L., Lokhorst, H., Dekker, A., Neiuwenhuis, G., and Peterson, E. Graft-versus-myeloma effect in two cases. Lancet, 347: 800-803, 1996.
65. Gahrton, G., Tura, S., Ljungman, P., Blade, J., Brandt, L., Cavo, M., Facon, T., Gratwohl, A., Hagenbeek, A., Jacobs, P., de Laurenzi, A., Van Lint, M., Michallet, M., Nikoskelainen, J., Reiffers, J., Samson, D., Verdonck, L., de Witte, T., and Volin, L. Prognostic factors in allogeneic bone marrow transplantation for multiple myeloma. J. Clin. Oncol., 13: 1312-1322, 1995.
66. Bensinger, W. I., Buckner, C. D., Anasetti, C., Clift, R., Storb, R., Barnett, T., Chauncey, T., Shulman, H., and Appelbaum, F. R. Allogeneic marrow transplantation for multiple myeloma: an analysis of risk factors on outcome. Blood, 88: 2787-2793, 1996.
67. Mehta, J., Tricot, G., Jagannath, S., Ayers, D., Singhal, S., Bracy, D., Siegel, D., Desikan, K. R., Munshi, N., Vesole, D., and Barlogie, B. A single-center, matched-pair comparison of auto and allografting in multiple myeloma. Blood, 88: 618a, 1996.
68. Bjorkstrand, B., Ljungman, P., Svensson, H., Hermans, J., Alegre, A., Apperley, J., Blade, J., Carlson, K., Cavo, M., Ferrant, A., Goldstone, A. H., de Laurenzi, A., Majolino, I., Marcus, R., Prentice, H. G., Remes, K., Samson, D., Sureda, A., Verdonck, L. F., Volin, L., and Gahrton, G. Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: a retrospective case-matched study from the European group for blood and marrow transplantation. Blood, 88: 4711-4718, 1996.
69. Anderson, K. C., Andersen, J., Soiffer, R., Freedman, A. S., Rabinowe, S. M., Robertson, M. J., Spector, N., Blake, K., Murray, C., Freeman, A., Coral, F., Marcus, K. D., Mauch, P., Nadler, L. M., and Ritz, J. Monoclonal antibody-purged bone marrow transplantation therapy for multiple myeloma. Blood, 82: 2568-2576, 1993.
70. Billadeau, D., Blacksadt, M., Greipp, P., Kyle, R. A., Oken, M. M., Kay, N., and Van Ness, B. Analysis of B-lymphoid malignancies using allele-specific polymerase chain reaction: a technique for sequential quantitation of residual disease. Blood, 78: 3021-3029, 1991.
71. Tricot, G., Barlogie, B., Jagannath, S., Vesole, D., Naucke, S., Tian, E., and Gazitt, Y. Double autotransplants can induce molecular remissions (MCR) in newly diagnosed patients with multiple myeloma (MM). Blood, 86: 969a, 1995.
72. Tricot, G., Gazitt, Y., Jagannath, S., Vesole, D., Reading, C., Juttner, C., Hoffman, R., and Barlogie, B. CD34+/THY-1+/LIN-peripheral blood stem cells (PBSC) effect timely trilineage engraftment in multiple myeloma (MM). Blood, 86: 207a, 1995.
73. Tricot, G., Jagannath, S., Desikan, K. R., Munshi, N., Siegel, D., Bracy, D., and Barlogie, B. Salvage transplant for early relapse (≤1 year) after a single autotransplant (AT) are effective and improve outcome. Blood, 88: 131a, 1996.
74. Munshi, N. C., Desikan, K. R., Jagannath, S., Siegel, D., Bracy, D., Tricot, G., and Barlogie, B. Dexamethasone, cyclophosphamide, etoposide an cis-platinum (DCEP), an effective regimen for relapse after high-dose chemotherapy and autologous transplantation (AT). Blood, 88: 586a, 1996.
75. Kwak, L. W., Taub, D. D., Duffey, P. L., Bensinger, W. I., Bryant, E. M., Reynolds, C. W., and Longo, D. L. Transfer of myeloma idiotype-specific immunity from an actively immunized marrow donor. Lancet, 345: 1016-1020, 1995.
76. Reichartdt, V., Okada, C., Benike, C., Long, G., Engleman, E., Blume, K., and Levy, R. Idiotypic vaccination using dendritic cells for multiple myeloma patients after autologous peripheral blood stem cell transplantation. Blood, 88: 481a, 1996.
77. Munshi, N. C., Govindarajan, R., Drake, R., Ding, L. M., Iyer, R., Saylors, R., Kornbluth, J., Marcus, S., Chiang, Y., Ennsit, D., Kwak, L., Reynolds, C., Tricot, G., and Barlogie, B. Thymidine kinase (TK) gene-transduced human lymphocytes can be highly purified, remain fully functional, and are killed efficiently with ganciclovir. Blood, 89: 1334-1340, 1997.
78. Munshi, N., Ding, L. M., Dahe, L., Kornbluth, J., Naugler, S., Mahavi, D., and Srivastava, A. GM-CSF transduction of the tumor cells provides lasting immune response in multiple myeloma. Blood, 88: 585a, 1996.
79. Piro, L. D., Carrera, C. J., Carson, D. A., and Beutler, E. Lasting remissions in hairy-cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine. N. Engl. J. Med., 322: 1117-1121, 1990.
80. Keating, M., Kantarjian, H., Talpaz, M., Redman, J., Koller, C., and Barlogie, B. Fludarabine. A new agent with major activity against a chronic lymphocytic leukemia. Blood, 74: 19-25, 1989.
81. Kraut, E. H., Crowley, J. J., Grever, M. R., Keppen, M. D., Bonnet, J. D., Hynes, H. E., and Salmon, S. E. Phase II study of fludarabine phosphate in multiple myeloma. Invest. New Drugs, 8: 199-200, 1990.